Shares of Insmed Inc. (INSM) are up an impressive 130% at $51 in pre-market trading Tuesday, thanks to positive topline results from the ASPEN study.ASPEN is a phase III trial of the company's investigational drug Brensocatib in patients with non-cystic fibrosis bronchiectasis.According to the results reported today, the study met its primary endpoint, with both dosage strengths, say 10mg and 25mg...
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.